Neoadjuvant Versus Adjuvant Systemic Therapy for Operable Breast Cancer-Reference-Cited by-同舟云学术

Neoadjuvant Versus Adjuvant Systemic Therapy for Operable Breast Cancer

Published:2013-02 Issue:2 Volume:257 Page:180-181
ISSN:0003-4932
Container-title:Annals of Surgery
language:en
Short-container-title:

Author:

Smith Barbara L.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Surgery

Reference7 articles.

1. Statement of the science concerning loco-regional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute Conference.;Buchholz;J Clin Oncol,2008

2. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.;Rastogi;J Clin Oncol,2008

3. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer Trial 10902.;van der Hage;J Clin Oncol,2001

4. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18.;Wolmark;Cancer,2001

5. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18.;Fisher;J Clin Oncol,1997

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and Validation of a Nomogram to Predict the Probability of Breast Cancer Pathologic Complete Response after Neoadjuvant Chemotherapy: A Retrospective Cohort Study;Frontiers in Surgery;2022-06-09

2. A nomogram based on clinicopathological features and serological indicators predicting breast pathologic complete response of neoadjuvant chemotherapy in breast cancer;Scientific Reports;2021-05-31

3. Surgery Following Primary Systemic Therapy: How to Increase Breast Conservation Rate;Oncoplastic Breast Surgery Techniques for the General Surgeon;2020

4. Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement;The Oncologist;2019-02-01

5. Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors;Brazilian Journal of Medical and Biological Research;2017